Australia-wide dispatch

Quantified
Peptides
AOD-9604 5mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

AOD-9604

Anti-Obesity Drug 9604, c-terminal fragment of HGH (177-191). Supplied as a lyophilised powder in 5mg vials.

Supplied as lyophilised powder in a 5mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About AOD-9604

Anti-Obesity Drug 9604

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

AOD-9604 (Anti-Obesity Drug 9604) is a 16-amino acid synthetic peptide fragment derived from the C-terminal region of human growth hormone (residues 177-191). It was developed by Monash University and studied as a potential treatment for obesity due to its proposed lipolytic properties.

Research has focused on its ability to stimulate fat cell lipolysis and inhibit lipogenesis through mechanisms distinct from full HGH. Unlike complete growth hormone, AOD-9604 does not appear to influence insulin sensitivity or promote cell proliferation in research models, making it a subject of interest for metabolic research.

Origin
C-terminal fragment of HGH (177-191)
Research Areas
Lipolysis, metabolic regulation
Amino Acids
16 residues
Molecular Weight
~1.8 kDa
Research Institution
Monash University
Mechanism
Beta-3 adrenergic receptor interaction
IGF-1 Effect
Minimal in research models
Research Focus
Lipolysis, fat oxidation
  1. 01LipolysisAOD-9604 is a fragment of human growth hormone (residues 177-191) studied for its effects on fat cell lipolysis. Research examines its ability to stimulate fat breakdown without the growth-promoting effects of full HGH.
  2. 02Beta-3 Adrenergic ActivityStudies have investigated AOD-9604 interactions with beta-3 adrenergic receptors in adipose tissue, proposing a mechanism by which fat oxidation may be enhanced in research models without systemic IGF-1 elevation.
  3. 03Metabolic RegulationUnlike full-length GH, AOD-9604 research has focused on metabolic effects without anabolic signalling. Research models suggest it may influence resting metabolic rate and lipid utilisation pathways.

References

  1. 1Ng FM et al. Metabolic studies of a growth hormone-releasing peptide. J Mol Endocrinol. 2000;24:25-34.
  2. 2Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604). Obesity. 2001;9(2):110-117.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=AOD-9604
  4. 4Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology. Endocrinol Metab Clin. 2012.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range